{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:26:05Z","timestamp":1788305165228,"version":"build-2803163510"},"reference-count":29,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,9,10]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>In a randomized phase 3 trial, overall response rates, PFS, and overall survival were similar between MPT-T and mPR-R. Toxicity with both regimens was common, but mPR-R was better tolerated, and patients on the mPR-R regimen reported better quality of life.<\/jats:p>","DOI":"10.1182\/blood-2014-12-613927","type":"journal-article","created":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T02:35:30Z","timestamp":1436409330000},"page":"1294-1301","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":80,"title":["Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma"],"prefix":"10.1182","volume":"126","author":[{"given":"A. Keith","family":"Stewart","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic Arizona, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Jacobus","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic Arizona, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Weiss","sequence":"additional","affiliation":[{"name":"Marshfield Clinic, Marshfield, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher A.","family":"Chanan-Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Jacksonville, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111905343635300_B1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis.","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"issue":"9","key":"2019111905343635300_B2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111905343635300_B3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111905343635300_B4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clml.2012.08.009","article-title":"Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.","volume":"13","author":"White","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"28","key":"2019111905343635300_B5","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111905343635300_B6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019111905343635300_B7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111905343635300_B8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2012.074534","article-title":"Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.","volume":"98","author":"Dimopoulos","year":"2013","journal-title":"Haematologica"},{"issue":"19","key":"2019111905343635300_B9","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"7-8","key":"2019111905343635300_B10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","article-title":"The randomization and stratification of patients to clinical trials.","volume":"27","author":"Zelen","year":"1974","journal-title":"J Chronic Dis"},{"key":"2019111905343635300_B11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.2517-6161.1989.tb01433.x","article-title":"Interim analyses: the repeated confidence interval approach.","volume":"51","author":"Jennison","year":"1989","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"3","key":"2019111905343635300_B12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials.","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"key":"2019111905343635300_B13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials.","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"2019111905343635300_B14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observation.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2019111905343635300_B15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2307\/2344317","article-title":"Asymptomatically efficient rank invariant test procedures.","volume":"135","author":"Peto","year":"1972","journal-title":"J Royal Stat Soc Ser A Stat Soc."},{"key":"2019111905343635300_B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3115-3","article-title":"Modelling Survival Data in Medical Research.","author":"Collett","year":"1994"},{"issue":"34","key":"2019111905343635300_B17","first-page":"181","article-title":"Regression models and life tables.","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"22","key":"2019111905343635300_B18","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.","volume":"32","author":"Uno","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111905343635300_B19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"2019111905343635300_B20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.1992.10.2.178","article-title":"Myeloma, melphalan, and meta-analysis.","volume":"10","author":"Bergsagel","year":"1992","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111905343635300_B21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/096368979600500304","article-title":"Blood stem cell collection: factors influencing the recovery of granulocyte-macrophage colony forming cells.","volume":"5","author":"Imrie","year":"1996","journal-title":"Cell Transplant"},{"issue":"7","key":"2019111905343635300_B22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/cncr.21342","article-title":"Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.","volume":"104","author":"Palumbo","year":"2005","journal-title":"Cancer"},{"issue":"9513","key":"2019111905343635300_B23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"7","key":"2019111905343635300_B24","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study.","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111905343635300_B25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3747\/co.2007.107","article-title":"Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial.","volume":"14","author":"White","year":"2007","journal-title":"Curr Oncol"},{"issue":"1","key":"2019111905343635300_B26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111905343635300_B27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111905343635300_B28","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111905343635300_B29","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/11\/1294\/1387862\/1294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/11\/1294\/1387862\/1294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T22:26:57Z","timestamp":1717972017000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/126\/11\/1294\/34394\/Melphalan-prednisone-and-thalidomide-vs-melphalan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,10]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-12-613927","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,10]]}}}